Nature Medicine, Published online: 11 August 2026; doi:10.1038/s41591-026-04529-w
As new drugs that target mutant RAS redefine the therapeutic landscape in the treatment of pancreatic cancer, understanding and intercepting resistance is critical; a new study reveals mechanisms of acquired genetic resistance to daraxonrasib, highlighting putative combination approaches.
